This MedLibrary.org supplementary page on Paromomycin sulfate is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Paromomycin sulfate
|
|
| Systematic (IUPAC) name | |
| (2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)- 4,6-diamino-2-[(2S,3R,4R,5R)-4-[(2R,3R,4R,5R,6S)- 3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl] oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy- 3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol |
|
| Identifiers | |
| CAS number | |
| ATC code | A07 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C23H47N5O18S |
| Mol. mass | 615.629 g/mol |
| Pharmacokinetic data | |
| Bioavailability | None |
| Metabolism | None |
| Half life | ? |
| Excretion | Fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status |
Rx only U.S. |
| Routes | Oral, intramuscular |
Paromomycin sulfate (brand name Humatin) is a aminoglycoside based drug that fights intestinal infections such as cryptosporidiosis and amoeba infection, or amoebiasis and was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005[1] and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.[2]
Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.[3]
As of February 5th, 2008, King Pharmaceuticals is discontinuing the sale of Humatin, Paromomycin continues to be available in the United States from another manufacturer. [1]
References
- ^ Institute for OneWorld Health (23 May 2005). "Institute for OneWorld Health Drug Receives “Orphan” Designation From U.S. and European Regulatory Agencies". Press release. Retrieved on 2007-02-10.
- ^ Institute for OneWorld Health (8 September 2006). "New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India". Press release. Retrieved on 2007-02-10.
- ^ Vicens, Quentin; Eric Westhof (August 2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure 9 (8): 647–658. doi:. PMID 11587639. Retrieved on 2007-02-10.
 |
This antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
|
||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 14 August 2008, at 12:56.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Paromomycin sulfate".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.